Abstract: A method of introducing a second stereogenic center into a tetrahydro-?-carboline have two stereogenic centers using a modified Pictet-Spengler reaction is disclosed. The method provides a desired cis- or trans-isomer in high yield and purity, and in short processes times.

Abstract: Compounds of formula (I) in which R1=C1-6 alkyl, optionally halosubstituted; R2=H, C1-4 alkyl, optionally halosubstituted or replaced by halogen; R3=C2-4 alkyl, optionally halosubstituted; R4=SO2NR5R&, CO2R7 or halogen, C2-4 alkenyl; optionally substituted with NR5R6, SONR5R6, CONR5R6, CO2R7 or halogen, C2-4 alkanoyl, optionally substituted with NR5R6, SONR5R6, CONR5R6, CO2R7 or halogen; R5 and R6=independently H or C1-4 alkyl, or, together with the N atom to which they are attached, a pyrrolidino, piperidino, morpholino, 4-(NR8)-1-piperazinyl or 1-imidazolyl ring optionally substituted with one or two C1-4 alkyl groups; R7=H, C1-4 alkyl, optionally fluorosubstituted, and R8=H,C1-3 alkyl or hydroxyalkyl with 1-4 C atoms, or the pharmaceutically acceptable salts thereof are useful for the chemotherapeutic treatment of neuropathies.

Abstract: A method of treating symptoms of benign prostatic hypertrophy and a method of treating lower urinary tract symptoms, are disclosed. The method includes administering to a mammal about 1 to about 20 milligrams of an agent that inhibits cyclic guanosine 3,5-monophosphate specific phosphodiesterase type 5.

Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents as inhibitors of phosphodiesterase 5 cardiovascular disorders

Abstract: Compounds of structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: Compounds of the general structural formula (I), and use of the compounds and salts and solvates thereof, as thereapeutic agents.

Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: Compounds of the general structural formula (I), and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.

Abstract: A method of treating female arousal disorder (FAD) in a female patient is disclosed. The method includes orally administering an agent that inhibits cyclic guanosine 3′5′-monophosphate specific phosphodiesterase type 5 to the female patient.

Abstract: The present invention relates to phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 10 mg unit dosage are useful for the treatment of sexual dysfunction by daily administration of the PDE5 inhibitor. The articles of manufacture described herein are characterized by PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, especially erectile dysfunction, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes and with an improvement of vascular conditioning.

Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction. The articles of manufacture described herein are characterized by selective PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes.